This class of medication mimics endogenous GLP-1 and stimulates the GLP-1 receptor, enhancing insulin secretion from the pancreatic islet cells, inhibiting glucagon release, and slowing gastric emptying, thus improving glycemic control, reducing post-prandial glucose spikes, enhancing satiety, and promoting weight loss [2,3,4]
Some medication always remains in the vial after the last full dose
These are the newer GLP-1 therapies that have shown superior results to prior therapies in lowering A1C (blood sugar) levels of diabetics and helping those who are obese lose weight
Preclinical studies in animal models demonstrate that the administration of BPC-157 accelerates the healing of both soft tissues and bone, including in challenging segmental defect models, where it stimulated the formation of mature lamellar bone instead of fibrous tissue [29]
Decker, H
Several companies are actively researching and producing foods that align with the GLP-1 properties trend